NUR 610 Module 2 Public Health Ethics and Genomics Discussion Example

Discussion Board: Public Health Ethics and Genomics

Should the Health Department Call Your Cousin? Kass's Framework and Family Contact in Genomic Screening

Initial Post

Last week I described how families often fail to pass on news of familial hypercholesterolemia (FH). This week I want to test an idea that has come up in my health department: offering to contact relatives directly, with the diagnosed patient's permission, to recommend cholesterol testing.

Clinical ethics would frame this mainly as a question of the patient's confidentiality and autonomy. Public health ethics asks a different question: whether a program serving a population is justified. Childress et al. (2002) describe general moral considerations in public health, such as doing good, avoiding harm, respecting autonomy, keeping information private and treating people fairly, and note that these can conflict. Kass (2001) offers a practical framework of six questions, which I applied to the proposal.

1. What are the public health goals? To reduce early heart attacks and deaths in families with FH by finding and treating affected relatives.

2. How effective is the program in achieving its goals? Cascade screening is widely recommended because each identified case can lead to several more, and treatment of FH lowers cardiovascular risk (Knowles et al., 2017). Direct contact by health professionals is likely more effective than family notification alone, though I would want local data.

3. What are the known or potential burdens? Privacy risks if relatives learn of a family member's diagnosis without consent; anxiety; possible concerns about insurance; and stigma in families where heart disease is linked to blame.

4. Can the burdens be reduced, or could another approach work? Yes: contact only with the index patient's written permission, letters that do not name the patient unless agreed, an option for the patient to notify relatives with health department support instead, and information about legal protections.

5. Is the program implemented fairly? Only if it reaches families who lack private specialists, which means offering it in Spanish and other languages and through community clinics, not only cardiology practices.

6. How can benefits and burdens be fairly balanced? Through community input, transparent policies and evaluation of who is reached.

Applying the framework moved me from enthusiasm to a conditional position. Direct contact is justified when the index patient consents and the program is designed to reach underserved families. Without those conditions, it risks harming privacy while mainly benefiting families who would have been found anyway.

The exercise also showed me the value of public health ethics for nurses. At the bedside, I would think only about my patient's wishes. In a population program, I also need to ask who benefits, who bears the burdens and whether the program is fair.

Reply to Priya

Amara, you argued that the duty to warn relatives should override confidentiality for serious, preventable genetic conditions. I understand the logic, especially for a condition like FH where treatment works. But Kass's framework made me hesitant to go that far. The program's effectiveness depends on trust, and if people believe a genetic test result might be shared without their consent, fewer may agree to testing in the first place. That would reduce the number of families found, the opposite of the goal. Kass's question about whether burdens can be minimized seems to favor approaches like supported notification, where the patient keeps control but receives help. I wonder whether your view would change for a condition where relatives face an immediate risk of death, such as a hereditary heart rhythm disorder, where waiting for consent might cost a life. That might be the case where a stronger duty is defensible. Even then, I think the health department would need clear criteria, published in advance, for when it would act without consent, so that patients deciding whether to be tested know the rules. Transparency seems to be what protects trust when the duty to warn and confidentiality collide.

Reply to James

James, your post contrasted Kass's framework with the principlism of bioethics, and I found your table helpful. One point I would add is that Kass explicitly includes fairness in implementation, asking not only whether a program works but whether it reaches people fairly. Principlism includes justice too, but in clinical ethics it often stays abstract. In genomics, this difference matters because new programs tend to reach people who are already well served. Your example of a hospital offering genomic sequencing to all patients would look different under Kass's framework if most uptake came from insured, English-speaking patients. Did you consider how the program might measure who participates, so the fairness question could be answered with data? That seems like the step most programs skip. Collecting data on language, insurance and race or ethnicity for every participant would let the program see early whether it is reaching only some families and adjust its outreach before the gap becomes permanent. It would also give the community advisory group something concrete to review.

References

Childress, J. F., Faden, R. R., Gaare, R. D., Gostin, L. O., Kahn, J., Bonnie, R. J., Kass, N. E., Mastroianni, A. C., Moreno, J. D., & Nieburg, P. (2002). Public health ethics: Mapping the terrain. Journal of Law, Medicine & Ethics, 30(2), 170-178. https://doi.org/10.1111/j.1748-720X.2002.tb00384.x

Kass, N. E. (2001). An ethics framework for public health. American Journal of Public Health, 91(11), 1776-1782. https://doi.org/10.2105/AJPH.91.11.1776

Knowles, J. W., Rader, D. J., & Khoury, M. J. (2017). Cascade screening for familial hypercholesterolemia and the use of genetic testing. JAMA, 318(4), 381-382. https://doi.org/10.1001/jama.2017.8543